Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases. The company focuses on developing melanocortin-4 receptor (MC4R) agonists as precision medicines designed to treat hyperphagia and severe obesity… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rhythm Pharmaceuticals, Inc. does
In the company’s own words
Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases. The company focuses on developing melanocortin-4 receptor (MC4R) agonists as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. www.rhythmtx.com
The company's lead asset, IMCIVREE (setmelanotide), is the first-ever therapy approved and marketed in the United States, European Union, United Kingdom, Canada, and several other countries for certain rare MC4R pathway diseases, including Bardet-Biedl syndrome and obesity caused by POMC, PCSK1, or LEPR deficiency. IMCIVREE is approved for use in patients aged two years and older. The company is advancing two earlier-stage investigational MC4R agonists: bivamelagon, an oral small molecule, and RM-718, designed for weekly subcutaneous administration. Both candidates are engineered to exhibit high selectivity for MC4R while functionally sparing MC1R, avoiding hyperpigmentation associated with earlier therapies.
Rhythm's clinical development pipeline addresses three key disease areas. The company is preparing for global commercialization of setmelanotide for acquired hypothalamic obesity beginning in 2026, pending regulatory approval. The company is also evaluating setmelanotide in congenital hypothalamic obesity and Prader-Willi syndrome, with preliminary Phase 2 data showing encouraging results in PWS. Additionally, the company is advancing its Phase 3 EMANATE trial, comprised of four independent substudies evaluating setmelanotide in genetically caused MC4R pathway diseases, with topline data expected in March 2026.
The company leverages what it believes is the largest known DNA database focused on obesity, containing approximately 120,000 sequencing samples as of December 31, 2025, to improve understanding, diagnosis, and care of patients with severe obesity due to MC4R pathway variants. As of February 1, 2026, Rhythm employed 414 people, including 126 employees in eleven countries outside North America. The company has generated approximately $422.5 million from product sales to date and maintains a global foundation with IMCIVREE achieving regulatory approvals and market access in more than twenty-five countries.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1649904
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rhythm Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Rhythm Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Rhythm Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rhythm Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rhythm Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rhythm Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”